Nomenclature of monoclonal antibodies

Views:
 
Category: Education
     
 

Presentation Description

how biologicals are named

Comments

Presentation Transcript

Nomenclature of monoclonal antibodies:

Nomenclature of monoclonal antibodies Prefix + Target/disease class infix + Source infix + Stem Avastin® BEXXAR® Erbitux® Herceptin® MabCampath® Mabthera® Mylotarg® Vectibix® YERVOY™ Zevalin®

!! ……….MAB:

!! ……….MAB Monoclonal Antibodies ( mAb ) Polyclonal mixtures of antibodies, "- pab “ order for combining the key elements of a monoclonal antibody name is as follows:  1 )  prefix 2 ) infix representing the target or disease  targets are tumors, organ systems like the circulatory system, or infectious agents like bacteria or  viruses 3 ) infix indicating the source 4 ) the stem used as a suffix.

History:

History Emil von Behring  and  Kitasato Shibasaburō  discovered in 1890 that  diphtheria and tetanus toxins were neutralized in the bloodstream of animals by substances they called   antitoxins , which were specific for the respective toxin

Hybridoma technology:

Hybridoma technology The principle of monoclonal antibody production: published in 1975 by Georges Köhler  and César Milstein Awarded the 1984 Medicine Nobel Prize for their discovery together with Niels Kaj Jerne Muromonab-CD3  was the first monoclonal antibody to be approved for clinical use in humans, in 1986

World Health Organization (WHO) :

World Health Organization (WHO) Introduced the system of International Nonproprietary Names in 1950 First INN list being published three years later Stem   - mab  for monoclonal antibodies was proposed around 1990 Current system with target and source substems was developed between 1991 and 1993 Collaboration between the WHO and the United States Adopted Names Council, antibody USANs have the same structure and are largely identical to INNs 170 monoclonal antibodies received names following this nomenclature

Target/Disease Class Infixes for Monoclonal Antibodies (infix, definition and example suffixes as used)::

Target/Disease Class Infixes for Monoclonal Antibodies (infix, definition and example suffixes as used): infix :  - tu -/-t- definition:  tumors example:  - tuzumab /- tumab /- tomab infix:  - li -/-l- definition:  immunomodulator example:  - liximab /- lumab /- lixizumab infix:  - ba -/-b- definition:  bacterial example:  - bixumab /- bumab infix:  - ci -/-c- definition:  cardiovascular example:  - cixumab /- cumab infix:  -fu-/-f- definition:  antifungal example:  - fuzumab /- fumab infix:  - ki -/-k- definition:  interleukins example:  - kiximab /- kumab infix:  -ne-/-n- definition:  neurons as targets example:  - nezumab /- numab infix:  -so-/-s- definition:  bone example:  - somab /- sumab infix:  -vi-/-v- definition:  viruses, antiviral indications example:  - vizumab /- vumab

Source Infixes Used Frequently:

Source Infixes Used Frequently infix :  - zu - definition:  humanized infix:  -o- definition:  mouse infix:  -u- definition:  fully human infix:  -xi- definition:  chimeric

PowerPoint Presentation:

  Human parts are shown in red, non-human parts in blue. mouse chimeric humanized chimeric/humanized Human

Revised nominclature:umab (human origin) :

Revised nominclature:umab (human origin) - Adalimumab , adecatumumab atinumab atorolimumab belimumab bertilimumab briakinumab brodalumab ……………………………………….. Regavirumab rilotumumab , robatumumab , roledumab , secukinumab sevirumab , sifalimumab , sirukumab stamulumab http://www.who.int/medicines/services/inn/BioRev2011.pdf

authorStream Live Help